ASCO Offers Glimpse Of LAG-3 Inhibitors’ Potential Opportunities – And Limitations
PD-1-Naïve Patients More Likely To Derive Benefit
Clinical data released on drugs targeting LAG-3 from BMS, Regeneron, Merck & Co. and Immutep in a variety of cancers.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: a ground-breaking approval for Alzheimer’s in the US; LAG-3 inhibitors and new Keytruda data generate excitement at ASCO; and clinical progress for another COVID-19 vaccine.
Data show better safety than Opdivo/Yervoy, though what appears to be slightly lower efficacy, in first-line metastatic or unresectable melanoma.
Following failure of Incyte/Merck's epacadostat/Keytruda study, NewLink Genetics says it is reviewing its IDO clinical programs.